Promoter mutations associated with hereditary persistence of fetal haemoglobin either disrupt repressors or create de novo sites for activators
ESH eLearning, Merlin Crossley, 265279
Managing CML in emerging regions: some problems and perspectives
ESH eLearning, Hemant Malhotra, 234664
Long-term survival of patients with chronic phase chronic myeloid leukemia who received autologous stem cell transplantation and further exposed to tyrosine kinase inhibitors
ESH eLearning, Mauricette Michallet, 234801
The technical decline in the rate of CML treatment-free remission in aging countries: the French experience
ESH eLearning, Marc Delord, 257017
Prevalence and outcomes of uncommon BCR-ABL fusion transcripts in patients with CML: data from a single center
ESH eLearning, Qian Jiang, 257018
Aim for the cure: TKI-based chemotherapy for Ph+ ALL
ESH eLearning, Elias Jabbour, 257019
Patients' perspectives on the definition of cure in chronic myeloid leukemia: a US based survey
ESH eLearning, Gemlyn George, 257030
Long-term results of a phase 2 trial of nilotinib 400 Mg twice daily in newly diagnosed patients with chronic phase of chronic myeloid leukemia
ESH eLearning, Lucia Masarova, 257031
Treatment-free remission in patients with chronic phase chronic myeloid leukemia and stable deep molecular response discontinuing dasatinib (DASFREE)
ESH eLearning, Susanne Saussele, 257032
Low-intensity TKI-based therapy for Ph+ ALL
ESH eLearning, Hervé Dombret, 234568
Impact of kinase domain mutations on second line nilotinib therapy In CML chronic phase – Real world data from a developing country perspective
ESH eLearning, Shinto Francis Thekkudan, 234569
Are TKI really safe?
ESH eLearning, C Gambacorti, 234570
Long-term impact of early and deeper molecular response in newly diagnosed CML-CP patients receiving radotinib: three years follow-up of rerise study
ESH eLearning, Young Rok Do, 234571
Molecular milestones using the BCR-ABL1 qPCR level and doubling time after imatinib discontinuation to predict successful treatment-free remission: treatment-free remission accomplished by dasatinib (TRAD) trial
ESH eLearning, Dennis KIM, 234573
Stem cell transplant for Ph+ ALL: who, when, how
ESH eLearning, Federico Lussana, 234797
How to identify and manage Ph-like ALL
ESH eLearning, Sarah Tasian, 234798
What prevents the disease from relapsing after TKI discontinuation
ESH eLearning, Satu Mustjoki, 234803
Loss of function of the SETD2 tumor suppressor is a recurrent event in advanced-phase chronic myeloid leukemia, is due to post-translational mechanisms and fosters genetic instability
ESH eLearning, Manuela Mancini, 257025
ESH eLearning, Michael Deininger, 257026
CML hematopoietic stem cells expressing IL-1RAP may be targets of chimeric antigen receptor (CAR) - engineered T-cells
ESH eLearning, Christophe Ferrand, 257027
A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies common drug resistance mechanisms 
ESH eLearning, Matthieu Lewis, 257028
Modulation of p53 with the MDM2 antagonist idasanutlin, in combination with nilotinib treatment, targets primitive CML cells in vitro and in vivo.
ESH eLearning, David Vetrie, 257029
ELN and real-word treatment algorithms for MPNs
ESH eLearning, Giuseppe Saglio, 234566
The association of transposable elements with chronic myeloid leukemia supports an assumption that non-coding variable regions of the human genome may play a role in hematological malignancies
ESH eLearning, Jitka Koblihova, 234567
HMGCLL1 Is a predictive germline biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
ESH eLearning, Dennis KIM, 234572
Bcl-2 and its inhibition in leukemia
ESH eLearning, Marina Konopleva, 234637
Novel approaches to monitor MPN
ESH eLearning, Jerry Radich, 234799
Resistance and progression to TKI: not just mutations
ESH eLearning, Jerry Radich, 234800
Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias
ESH eLearning, Justin Pritchard, 234802
Nilotinib vs. Nilotinib plus interferon α induction and nilotinib or interferon α maintenance therapy for newly diagnosed BCR-ABL positive. Chronic myeloid leukemia patients in chronic phase: interim analysis of the tiger (CML V) trial
ESH eLearning, Andreas Hochhaus, 257020
Spirit 2: final analysis of an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML
ESH eLearning, Stephen OBrien, 257021
TNFα-induced bone marrow stromal niche alterations enhance leukemic stem cell growth via CXCL1/CXCR2 signaling
ESH eLearning, Puneet Agarwal, 257022
Identification of metabolic vulnerabilities in leukemic stem cells using the integrative omic approach 
ESH eLearning, Zuzana Brabcova, 257023
Minimal, measurable, atypical
ESH eLearning, Nick Cross, 257024
Why the fuss over CML stem cells ?
ESH eLearning, Robert Peter Gale, 234565
ESH eLearning, Jason Gotlib, 219417
Are we using personalized treatment for patients with myelofibrosis?
ESH eLearning, Alessandro Vannucchi, 219254
Epigenetics in myeloproliferative neoplasms
ESH eLearning, Mary-Frances McMullin, 219251
Dissecting the molecular genetics of MPN
ESH eLearning, Ann Mullally, 219252
Stem cell depletion therapy is needed to change the natural history of the MPNs
ESH eLearning, Ronald Hoffman, 219253
Somatic mutations and clonal relationships
ESH eLearning, Peter Campbell, 219247
MPN Drivers: from active JAK2 and TpoR mutants to rogue calreticulin and their role in progression
ESH eLearning, Stefan N Constantinescu, 219248
Role of epigenetic dysregulation in MPN pathogenesis
ESH eLearning, Ross L. Levine, 219249
Megakaryocyte differentiation therapy in the MPNs
ESH eLearning, John D. Crispino, 219250
Antibodies & antibody conjugates
ESH eLearning, Wendy Stock, 219267
CAR T-cells
ESH eLearning, Noëlle Frey, 219268
Treatment of poor ELN risk AML
ESH eLearning, Richard Schlenk, 219258
Salvage therapy
ESH eLearning, Arnold Ganser, 219259
FLT3 inhibitors
ESH eLearning, M Levis, 219260
IDH inhibitors
ESH eLearning, Eytan Stein, 219261
Therapy of acute promyelocytic leukemia
ESH eLearning, Lionel Adès, 219262
Gemtuzumab Ozogamicin
ESH eLearning, Alan Burnett, 219263
Maintenance therapy after transplantation
ESH eLearning, Charles Craddock, 219264
Low-intensity treatments
ESH eLearning, Hervé Dombret, 219265
Tumor target antigens in AML
ESH eLearning, Marion Subklewe, 219266
Diagnosis of ph-like ALL
ESH eLearning, Charles Mullighan, 219255
Leukemic stem cells modulate the bone marrow microenvironment
ESH eLearning, Bonnet Dominique, 219256
Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity? - No
ESH eLearning, Farhad Ravandi-Kashani, 219257
Understanding gene-gene interactions via machine learning: Pandora’s box?
ESH eLearning, Andrew Wei, 226246
Improving the activity of BH3 mimetic venetoclax: a case study
ESH eLearning, Andrew Wei, 226247
Clinical trials investigating venetoclax combinations for AML
ESH eLearning, Andrew Wei, 226248
An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
ESH eLearning, Arnold Ganser, 226249
The devastating effects of relapsed or refractory AML
ESH eLearning, Arnold Ganser, 226250
From bench to the bedside: understanding the genetic changes in AML
ESH eLearning, Arnold Ganser, 226251
Finding the right targets for CAR T-cell therapy in AML
ESH eLearning, Arnold Ganser, 226252
Midostaurin: the first drug to receive approval for AML since 2000
ESH eLearning, Arnold Ganser, 226253
Overcoming the issues with clinical trial recruitment
ESH eLearning, Arnold Ganser, 226254
Transplantation clinical trial network to build available prospective studies on AML
ESH eLearning, Charles Craddock, 226255
Current understandings of ALL approaches
ESH eLearning, Charles Craddock, 226256
Challenges with the identification of ALL subtypes
ESH eLearning, Charles Craddock, 226257
Improving response to ALL therapies
ESH eLearning, Charles Craddock, 226258
Minimal residual disease: a key determinant of ALL treatment response
ESH eLearning, Charles Craddock, 226259
Increasing the effectiveness of ALL therapies
ESH eLearning, Charles Craddock, 226260
Combination therapy for the treatment of AML
ESH eLearning, Christoph Röllig, 226261
Applying the right therapies to the right AML patient population
ESH eLearning, Christoph Röllig, 226262
MRD detection techniques in AML: pros and cons
ESH eLearning, Christoph Röllig, 226263
Immunotherapies for the treatment of AML
ESH eLearning, Christoph Röllig, 226264
Managing AML in elderly patients
ESH eLearning, Christoph Röllig, 226265
Biological rationales when determining AML therapies
ESH eLearning, Christoph Röllig, 226266
Targeting IDH mutations for the treatment of AML
ESH eLearning, Eytan Stein, 226267
Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?
ESH eLearning, Eytan Stein, 226268
Primary and secondary resistance in AML
ESH eLearning, Eytan Stein, 226269
Encouraging patients to participate in AML trials
ESH eLearning, Eytan Stein, 226270
The latest clinical trials into novel AML therapies
ESH eLearning, Eytan Stein, 226271
The complications of treating elderly patients with AML
ESH eLearning, Gail Roboz, 226272
Managing relapse in AML: the role of MRD
ESH eLearning, Gail Roboz, 226273
Combining existing drugs for the creation of novel AML therapies
ESH eLearning, Gail Roboz, 226274
Increasing AML clinical trial participation rates
ESH eLearning, Gail Roboz, 226275
The challenges of choosing the right target antigen in AML compared to ALL
ESH eLearning, Marion Subklewe, 226276
Exciting immunotherapy clinical trials for the management of AML
ESH eLearning, Marion Subklewe, 226277
How can we improve CAR T-cell therapy?
ESH eLearning, Marion Subklewe, 226278
Immunotherapy clinical trial participation in R/R AML
ESH eLearning, Marion Subklewe, 226279
Involving the patient is a key part of cancer treatment
ESH eLearning, Mark Levis, 226280
CAR T-cell therapy and ALL: the current landscape
ESH eLearning, Noelle Frey, 226281
The CAR T-cell therapy race
ESH eLearning, Noelle Frey, 226282
The importance of MRD assessment in all phases of ALL treatment
ESH eLearning, Noelle Frey, 226283
Next-generation methodologies: the future for MRD monitoring in ALL?
ESH eLearning, Wendy Stock, 226284
Emerging novel approaches for ALL: inotuzumab ozogamicin
ESH eLearning, Wendy Stock, 226285
Support systems are a crucial factor in ALL treatment
ESH eLearning, Wendy Stock, 226286
Bone marrow transplant in red cell disorders
ESH eLearning, eliane Gluckman, 219043

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings